Xerostomia Therapeutics Market to Witness Significant Growth of USD $2.79 Billion with 4.3% CAGR by 2030

 The Business Research Company’s 2026 market reports introduce new features such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, all designed to enhance the depth, usability, and strategic value of the insights provided.

How Will the Market Growth Rate of the Xerostomia Therapeutics Market Impact Future Demand?
The xerostomia therapeutics market size has grown steadily in recent years. It will grow from $2.24 billion in 2025 to $2.35 billion in 2026 at a compound annual growth rate (CAGR) of 5.0%. The growth in the historic period can be attributed to aging population, widespread use of xerogenic drugs, rising prevalence of chronic diseases, increased dental awareness, hospital-based symptom management.

The xerostomia therapeutics market size is expected to see steady growth in the next few years. It will grow to $2.79 billion in 2030 at a compound annual growth rate (CAGR) of 4.3%. The growth in the forecast period can be attributed to growth in otc product availability, increasing cancer therapy side effects, rising self-medication trends, expansion of pharmacy networks, higher focus on quality of life treatments. Major trends in the forecast period include rising incidence of medication-induced dry mouth, growing demand for over-the-counter therapies, increased adoption of artificial saliva products, expansion of retail and mail-order pharmacies, higher focus on oral symptom management.

Claim your free report sample now:
https://www.thebusinessresearchcompany.com/report/xerostomia-therapeutics-global-market-report

Who Are the Major Contributors to the Xerostomia Therapeutics Market Growth?
The rising prevalence of chronic diseases is expected to propel the growth of the xerostomia therapeutics market going forward. Chronic diseases refer to long-lasting medical conditions that persist for months or years, often progressing slowly and requiring ongoing management. The rising prevalence of chronic diseases is primarily due to sedentary lifestyles, as lack of regular physical activity contributes to obesity, cardiovascular problems, diabetes, and other long-term health conditions. Xerostomia therapeutics support chronic diseases by alleviating dry mouth symptoms and improving oral health, nutrition, and medication adherence, which are critical factors in managing long-term conditions. For instance, in June 2024, according to the National Health Service, a UK-based government department, 3,615,330 individuals registered with a general practitioner (GP) were diagnosed with non-diabetic hyperglycemia or pre-diabetes (a condition with elevated blood sugar levels, not high enough to be classified as diabetes) in 2023, marking an 18% increase from 3,065,825 cases in 2022. Therefore, the rising prevalence of chronic diseases is driving the growth of the xerostomia therapeutics market.

How Is the Xerostomia Therapeutics Market Mapped Across Its Segment Categories?
The xerostomia therapeutics market covered in this report is segmented –

1) By Type: Artificial Saliva Or Saliva Substitutes, Salivary Stimulants
2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Drug Stores, Mail Order Pharmacies, Hypermarkets And Supermarkets
3) By End-User: Adult, Pediatric

Subsegments:
1) By Artificial Saliva Or Saliva Substitutes: Oral Sprays, Gels, Lozenges, Mouthwashes
2) By Salivary Stimulants: Prescription Drugs, Over-The-Counter (Otc) Products, Chewing Gums And Lozenges

Which Trends Are Positively Affecting the Xerostomia Therapeutics Market Expansion?
Major companies operating in the xerostomia therapeutics market are focusing on patient-friendly, non-invasive treatments, such as oral sprays that provide precise topical lubrication and protective barrier coverage across the mouth to relieve dry-mouth symptoms and support oral health. Oral sprays for xerostomia refer to formulations delivered as fine mist directly onto the oral mucosa (tongue, palate, inner cheeks) which form either a hydrating film or lipid-based coating to reduce moisture evaporation, enhance lubrication during chewing/swallowing/speaking, and deliver longer duration relief in patients prone to dry mouth. For instance, in July 2023, K Pharmaceuticals, a US-based (India-origin reference notwithstanding) pharmaceutical company, launched Aquoral, a clinically-proven oral spray for managing xerostomia that uses patented Oxidized Glycerol Triesters (OGT) lipid technology to form a long-lasting protective barrier over the oral cavity, offering up to six hours of relief, enabling two quick sprays, and reducing the need for frequent reapplication compared to aqueous-based treatments.

Who Are the Key Players Driving the Xerostomia Therapeutics Market?
Major companies operating in the xerostomia therapeutics market are GlaxoSmithKline plc, Colgate-Palmolive Company, Sun Pharmaceutical Industries Ltd., Cipla Ltd., Synedgen Inc., Mission Pharmacal Company, Dentaid Ltd., Sunstar Suisse S.A., Forward Science Holding Inc., OraCoat, Oralieve UK Ltd., OraPharma Inc., OraVital Inc., Saliwell Limited, Bayer AG, 3M Company, Church & Dwight Co. Inc., Hikma Pharmaceuticals PLC, Lupin Limited, Teva Pharmaceutical Industries Ltd.

Get the full xerostomia therapeutics market report here:
https://www.thebusinessresearchcompany.com/report/xerostomia-therapeutics-global-market-report

Which Regions Are Forecasted to Experience the Fastest Growth in the Xerostomia Therapeutics Market?
North America was the largest region in the xerostomia therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the xerostomia therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Contact Us:

The Business Research Company: Global Market Research Reports & Consulting | The Business Research Company
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: info@tbrc.info

Follow Us On:

LinkedIn: The Business Research Company | LinkedIn